Introduction {#s1}
============

The prevalence of chronic kidney disease (CKD) is approximately 10% in several countries [@pone.0087604-Coresh1]--[@pone.0087604-Zhang1]. CKD patients have high risk for cardiovascular disease and death [@pone.0087604-Go1]. Genetic factors, including ethnicity [@pone.0087604-Li1] and family history of disease [@pone.0087604-Tsai1], , play a key role in CKD pathogenesis. Thus, it is desirable to identify candidate genes and evaluate their effects.

The renin--angiotensin system (RAS) regulates blood pressure and electrolyte balance [@pone.0087604-Remuzzi1]. Owing to the key role of angiotensin-converting enzyme (ACE) in RAS, ACE polymorphisms have frequently been investigated. One of the most important ACE polymorphisms is a 287-bp insertion/deletion in intron 16 (ACE I/D), and a previous study revealed a significant effect of this polymorphism on ACE gene expression [@pone.0087604-Mizuiri1]. Most studies have found that carriers of the D allele had a higher risk of CKD or end-stage renal disease (ESRD) than those of the I allele [@pone.0087604-Qin1]--[@pone.0087604-Zhou1].

Because previous studies have found that gender and the DD genotype had an additive effect on blood ACE levels [@pone.0087604-Zhang2], we hypothesized that gender differences affect the relative risk of ACE I/D polymorphisms for CKD. Numerous studies of CKD or ESRD have reported appreciable, but not significant, gender-dependent effects of ACE I/D polymorphisms [@pone.0087604-Mansoor1]--[@pone.0087604-Tomino1], but the populations used in these studies were of different ethnicities. Studies of Caucasian subjects have indicated additive effects of the D allele in females [@pone.0087604-Mansoor1]--[@pone.0087604-PalomoPinon1], but studies of Asian subjects have shown different results [@pone.0087604-Nakajima1]--[@pone.0087604-Tomino1]. Although many previous meta-analysis studies investigating ACE I/D polymorphisms and CKD have been reported, but no studies have considered moderate effects of gender in our knowledge [@pone.0087604-Qin1]--[@pone.0087604-Zhou1], [@pone.0087604-Zhou2]--[@pone.0087604-Yu1]. This study focused on general population without genetic abnormality or rare disorder, and we wanted to compare the risk of CKD in people with major allele (I allele) or minor allele (D allele) on ACE I/D. In addition, gender-dependent effects of ACE I/D polymorphisms on CKD risk was investigated.

Methods {#s2}
=======

Search Methods and Criteria for Considering Studies {#s2a}
---------------------------------------------------

The PRISMA 2009 Checklist was reported in [Table S1](#pone.0087604.s001){ref-type="supplementary-material"}. This study focused on the general population without genetic predisposing factors, and aimed to compare CKD risk between individuals carrying the major (I) and minor (D) alleles of ACE I/D. To identify relevant studies, English-language articles in MEDLINE, Cochrane Library and EMBASE were searched using relevant text words and medical subject headings that included all spellings of ACE I/D and CKD (the detailed search strategy is shown in [Table S2](#pone.0087604.s002){ref-type="supplementary-material"}). All articles published from the dates of inception of these medical databases to January 2013 were included. We manually scanned the reference lists of identified trials and review articles to avoid missing any other relevant studies [@pone.0087604-Qin1]--[@pone.0087604-Zhou1], [@pone.0087604-Zhou2]--[@pone.0087604-Yu1].

All related studies assessing the association between ACE I/D polymorphisms and CKD risk were considered for inclusion. The criteria for inclusion of a study were as follows: (1) cross-sectional surveys or case--control studies; (2) CKD defined according to the National Kidney Foundation: kidney damage by clinical diagnosis or a glomerular filtration rate \<60 ml/min/1.73 m^2^; (3) presence of a control group with normal kidney function; (4) study population age \>18 years; (5) Asian or Caucasian ethnicity of the populations, and (6) articles providing detailed distribution of ACE genotypes. Studies investigating the relationships between genetic polymorphisms and other kidney diseases (lupus nephritis, polycystic kidney disease, endemic nephropathy, or reflux nephropathy) were excluded.

Data Extraction and Quality Assessment {#s2b}
--------------------------------------

Two reviewers (Chin Lin and Sui-Lung Su) independently extracted the data and assessed risk of bias. We recorded the first author's name, year of publication, ethnicity of the study population, kidney function of the cases, definition of the case group and its population characteristics (mean age, proportion of male subjects, body mass index, diabetes mellitus prevalence, hypertension prevalence, and ACE I/D genotype distribution). Ethnicity of the study population was categorized by study area. Subjects in the Arabian peninsula were classified as Caucasian because Arabs were the main race, and subjects in other regions of Asia (excluding Russia) were classified as Asian. Diabetes mellitus and hypertension were defined by plasma glucose level of \>126 mg/dL and systolic blood pressure of \>140 mmHg. If the article did not report the prevalence of diabetes mellitus and hypertension or the definition did not match, we assumed a normal distribution of plasma glucose level and systolic blood pressure for calculation.

Estimating moderate effects is difficult in meta-analysis using case--control studies. Researchers prefer that studies provide stratified data or matching data, but previous studies have seldom reported these. Fortunately, the characteristics of case groups may be used to estimate moderate effects under the following two conditions: (1) outcomes were rare events, (2) the major independent variable and moderators were independent events.

For example, when the major independent variable is exposure, with values "yes" or "no," and the moderator is gender, with values "male" or "female," the variables *p* ~1~, *p* ~2~, *p* ~3~, and *p* ~4~ are the outcome prevalence of women without exposure, men without exposure, women with exposure, and men with exposure. The variable *p* ~5~ is the proportion of individuals with exposure in the whole population; *p* ~6~ is the proportion of men in the population without exposure; and *p* ~7~ is the proportion of men in the population with exposure.

When researchers wish to conduct a case--control study, they must survey the exposure proportion in the case and control groups to estimate the odds ratio (OR). The exposure proportions using a stratified view and ORs are as follows:

Exposure proportion among case women:

Exposure proportion among case men:

Exposure proportion among control women:

Exposure proportion among control men:

OR in women:

OR in men:

Crude OR (simple combined):

.

*k* ~1~ = proportion of males in the case group.

*k* ~2~ = proportion of males in the control group.

Two factors (*k* ~1~ and *k* ~2~) may affect the crude OR. However, when *p* ~1~, *p* ~2~, *p* ~3~, and *p* ~4~ are very rare and there is no association between the major independent variable and the moderator (*p* ~6~ = *p* ~7~),

If moderate effects are present (*OR* ~women~ ≠ *OR* ~men~), the proportion of males in the case group (*k* ~1~) is the only factor that can affect the crude OR. In addition, the relationship between *k* ~1~ and log of odds ratio approximate the first order polynomial when above assumption were proper. We may accordingly use the characteristics of the case group to estimate the moderate effects in this study under the above assumptions.

Risk of bias was assessed by the following procedures suggested by the Newcastle--Ottawa Quality Assessment Scale [@pone.0087604-Wells1] (shown in [Table S3](#pone.0087604.s003){ref-type="supplementary-material"}). This tool assesses studies with a focus on the following factors: (1) selection of study population, (2) comparability between the case and control groups, and (3) the exposure assessed. Each study received a score between 0 and 9. We investigated the relationship between the quality of studies and the estimation of risk.

Statistical Analysis {#s2c}
--------------------

Variables are presented as means, proportions, or numbers as appropriate. Our meta-analysis examined the association between ACE I/D polymorphisms and CKD risk for each study by odds ratios (ORs) with 95% confidence intervals (CIs).

The τ^2^ statistic estimated by the DerSimonian--Laird method was used for the assessment of heterogeneity, and a random-effects model based on the Mantel--Haenszel method was applied. Allele type, genotype, and dominant/recessive models were used to calculate the association between genetic polymorphism and CKD risk. This report displays results from the allele type model, unless estimates using a different model were obviously different. Egger's regression was used to test symmetry of pooled results. Prespecified subgroup analyses included the causes of CKD.

A moderate effect was defined as ratio between ORs in a stratified analysis. For example, if OR for the association between ACE I/D polymorphisms and CKD risk is 6 in the Asian group and 3 in the Caucasian group, the moderate effect of ethnicity will be 6/3 = 2. Possible moderators (ethnicity, age, gender, body mass index, diabetes mellitus, and hypertension) and study characteristic (quality score, study design, and kidney functions of cases) were tested by meta-regression. In multivariable analyses, we adjusted ethnicity because most previous studies have found significant moderate effects [@pone.0087604-Qin1]--[@pone.0087604-Zhou1]. To assess the effect of ethnicity on gender-dependent effects, we investigated the interaction between gender and ethnicity. The interaction between other moderators and gender were also tested.

This study considered a p-value of \<0.05 as significant for all analyses. Statistical analyses were carried out with R, version 2.15.0, using the "metafor" [@pone.0087604-Viechtbauer1] and "meta" [@pone.0087604-Schwarzer1] packages.

Results {#s3}
=======

Screening Process {#s3a}
-----------------

Our search strategy returned 501 papers (the identification process is shown in [Figure 1](#pone-0087604-g001){ref-type="fig"}). We excluded 249 papers after a preliminary search of titles and abstracts. An additional 129 papers were excluded after full-text articles were assessed, leaving 123 articles that matched our criteria. Of these, 15 used duplicate databases, 9 lacked detailed data, and 1 likely reported wrong data. In 98 of the studies finally included [@pone.0087604-Mansoor1]--[@pone.0087604-Tomino1], [@pone.0087604-Lee1]--[@pone.0087604-Powrie1], 2 (Zsom et al. [@pone.0087604-Zsom1] and Lee et al. [@pone.0087604-Lee1]) reported results of stratification, but studies by Zsom et al. [@pone.0087604-Zsom1] used a single control group. Accordingly, 99 populations were included in this meta-analysis, and their detailed data are shown in [Tables 1](#pone-0087604-t001){ref-type="table"} and [2](#pone-0087604-t002){ref-type="table"}.

![Flow diagram of identification process for eligible studies in this study.\
n: number of studies were deleted for aforementioned reasons.](pone.0087604.g001){#pone-0087604-g001}

10.1371/journal.pone.0087604.t001

###### Characteristics of published studies included in this meta-analysis.

![](pone.0087604.t001){#pone-0087604-t001-1}

  First author & year                                             Ethnicity   Studydesign   CKDtype   Kidneyfunctionof case                         Definition of case
  -------------------------------------------------------------- ----------- ------------- --------- ----------------------- -----------------------------------------------------------------
  Shaikh, 2012 [@pone.0087604-Shaikh1]                            Caucasian       CC          DN            non-ESRD                                UAE \>300 mg/day11
  Rahimi, 2012 [@pone.0087604-Rahimi1]                            Caucasian       CS          DN            non-ESRD                                   ACR \>30 mg/g
  El-Baz, 2012 [@pone.0087604-ElBaz1]                             Caucasian       CS          DN            non-ESRD                                   ACR \>30 mg/g
  Zsom(1), 2011 [@pone.0087604-Zsom1]                             Caucasian       CC        non-DN          non-ESRD             biopsy, ultrasound diagnosed & eGFR \<60 ml/min/1.73 m^2^
  Zsom(2), 2011 [@pone.0087604-Zsom1]                             Caucasian       CC          DN            non-ESRD                     proteinuria & eGFR \<60 ml/min/1.73 m^2^
  Al-Harbi, 2011 [@pone.0087604-AlHarbi1]                         Caucasian       CC          DN            non-ESRD                                  no description
  Jung, 2011 [@pone.0087604-Jung1]                                  Asian         CC          GN            non-ESRD                                 biopsy diagnosed
  Ali, 2011 [@pone.0087604-Ali1]                                    Asian         CC         Comb             ESRD                                   doctor diagnosed
  Huang, 2010 [@pone.0087604-Huang1]                                Asian         CC          GN              ESRD                                   biopsy diagnosed
  Jayapalan, 2010 [@pone.0087604-Jayapalan1]                        Asian         CS          DN            non-ESRD                               ACR \>30 mg/g or RRT
  Mansoor, 2010 [@pone.0087604-Mansoor1]                          Caucasian       CS          DN            non-ESRD                                albuminuria or RRT
  Naresh, 2009 [@pone.0087604-Naresh1]                              Asian         CC          DN            non-ESRD                                  no description
  Ezzidi, 2009 [@pone.0087604-Ezzidi1]                            Caucasian       CS          DN            non-ESRD                    ACR \>30 mg/g or eGFR \<90 ml/min/1.73 m^2^
  Nikzamir, 2009 [@pone.0087604-Nikzamir1]                        Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Anbazhagan, 2009 [@pone.0087604-Anbazhagan1]                      Asian         CC         Comb             ESRD                                          RRT
  Ahluwalia, 2009 [@pone.0087604-Ahluwalia1]                        Asian         CC          DN            non-ESRD                      UAE \>200 µg/min, ACR \>300 mg/g orRRT
  Palomo-Piñón, 2009 [@pone.0087604-PalomoPinon1]                 Caucasian       CS          DN            non-ESRD                                   ACR \>30 mg/g
  Möllsten, 2008 [@pone.0087604-Mollsten1]                        Caucasian       CS          DN            non-ESRD                                   ACR \>20 mg/g
  Eroglu, 2008 [@pone.0087604-Eroglu1]                            Caucasian       CC          DN            non-ESRD                            30 mg/day\<UAE \<300 mg/day
  Arfa, 2008 [@pone.0087604-Arfa1]                                Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Tripathi, 2008 [@pone.0087604-Tripathi1]                          Asian         CC        non-DN            ESRD                 CCr \<15 mL/min/1.73 m^2^ & ultrasound diagnosedor CT
  Movva, 2007 [@pone.0087604-Movva1]                                Asian         CC          DN              ESRD                          SCr \>1.5 mg/dL and UAE \>30 mg/day
  Uddin, 2007 [@pone.0087604-Uddin1]                                Asian         CC          DN              ESRD                                      porteinuria
  Buraczynska, 2006 [@pone.0087604-Buraczynska1]                  Caucasian       CC         Comb             ESRD                                          RRT
  So, 2006 [@pone.0087604-So1]                                      Asian         CS          DN            non-ESRD                                   ACR \>30 mg/g
  Shestakova, 2006 [@pone.0087604-Shestakova1]                    Caucasian       CC          DN            non-ESRD                                  ACR \>300 mg/g
  Ng, 2006 [@pone.0087604-Ng1]                                    Caucasian       CS          DN            non-ESRD          urinalyses positive, ACR \>250 mg/g (men) or \>355 mg/g (women)
  Prasad, 2006 [@pone.0087604-Prasad1]                              Asian         CC          DN            non-ESRD                           SCr \>3 mg/dL?ACR \>200 mg/g
  Degirmenci, 2005 [@pone.0087604-Degirmenci1]                    Caucasian       CS          DN              ESRD                                    UAE \>30 mg/day
  van der Sman-de Beer, 2005 [@pone.0087604-vanderSmandeBeer1]    Caucasian       CC         Comb           non-ESRD                                        RRT
  Park, 2005 [@pone.0087604-Park1]                                  Asian         CC          DN              ESRD                                          RRT
  Canani, 2005 [@pone.0087604-Canani1]                            Caucasian       CS          DN            non-ESRD                                  UAE \>20 µg/min
  Fabris, 2005 [@pone.0087604-Fabris1]                            Caucasian       CC          HN            non-ESRD                                  SCr \>1.5 mg/dL
  Lau, 2004 [@pone.0087604-Lau1]                                    Asian         CC          GN              ESRD                                   biopsy diagnosed
  Suzuki, 2004 [@pone.0087604-Suzuki1]                              Asian         CC          GN            non-ESRD                                 biopsy diagnosed
  Stratta, 2004 [@pone.0087604-Stratta1]                          Caucasian       CC          GN            non-ESRD                                 biopsy diagnosed
  Lochynska, 2003 [@pone.0087604-Lochynska1]                      Caucasian       CC          GN            non-ESRD                                 biopsy diagnosed
  Papp, 2003 [@pone.0087604-Papp1]                                Caucasian       CC          GN              ESRD                                          RRT
  Aucella, 2003 [@pone.0087604-Aucella1]                          Caucasian       CC         Comb           non-ESRD                                        RRT
  Okuno, 2003 [@pone.0087604-Okuno1]                                Asian         CS          DN            non-ESRD                                  UAE \>10 µg/min
  Ortiz, 2003 [@pone.0087604-Ortiz1]                              Caucasian       CC        non-DN          non-ESRD                             CCr \<50 mL/min/1.73 m^2^
  Hadjadj, 2003 [@pone.0087604-Hadjadj1]                          Caucasian       CC          DN            non-ESRD                      urinary albumin concentration \>20 mg/L
  Wang, 2003 [@pone.0087604-Wang2]                                  Asian         CC         Comb             ESRD                                          RRT
  Dixit, 2002 [@pone.0087604-Dixit1]                              Caucasian       CC          GN              ESRD                                   biopsy diagnosed
  Lee(1), 2002 [@pone.0087604-Lee1]                                 Asian         CS        non-DN          non-ESRD                         UAE \>20 µg/min or ACR \>20 mg/g
  Lee(2), 2002 [@pone.0087604-Lee1]                                 Asian         CS          DN            non-ESRD                         UAE \>20 µg/min or ACR \>20 mg/g
  Losito, 2002 [@pone.0087604-Losito1]                            Caucasian       CC         Comb             ESRD                                          RRT
  Yoon, 2002 [@pone.0087604-Yoon1]                                  Asian         CC          GN            non-ESRD                                 biopsy diagnosed
  Fradin, 2002 [@pone.0087604-Fradin1]                            Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Drouet, 2002 [@pone.0087604-Drouet1]                            Caucasian       CC          GN            non-ESRD                                 biopsy diagnosed
  Nicod, 2002 [@pone.0087604-Nicod1]                              Caucasian       CC         Comb           non-ESRD                                        RRT
  Araz, 2001 [@pone.0087604-Araz1]                                Caucasian       CS          DN            non-ESRD                                   ACR \>30 mg/g
  Azar, 2001 [@pone.0087604-Azar1]                                Caucasian       CC          DN            non-ESRD                                  UAE \>30 mg/day
  Lovati, 2001 [@pone.0087604-Lovati1]                            Caucasian       CC         Comb             ESRD                                          RRT
  Wang, 2001 [@pone.0087604-Wang3]                                Caucasian       CS         Comb           non-ESRD                             CCr \<60 mL/min/1.73 m^2^
  Taniwaki, 2001 [@pone.0087604-Taniwaki1]                          Asian         CS          DN            non-ESRD                                  UAE \>30 mg/day
  Viswanathan, 2001 [@pone.0087604-Viswanathan1]                    Asian         CC          DN            non-ESRD                              proteinuria \>500 mg/dL
  Hadjadj, 2001 [@pone.0087604-Hadjadj2]                          Caucasian       CS          DN            non-ESRD                      urinary albumin concentration \>20 mg/L
  Wu, 2000 [@pone.0087604-Wu1]                                      Asian         CC          DN            non-ESRD                                  no description
  Hsieh, 2000 [@pone.0087604-Hsieh1]                                Asian         CC          DN            non-ESRD                              proteinuria \>500 mg/dL
  van Ittersum, 2000 [@pone.0087604-vanIttersum1]                 Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Tomino, 1999 [@pone.0087604-Tomino1]                              Asian         CS          DN            non-ESRD                         UAE \>20 µg/min or ACR \>30 mg/g
  Solini, 1999 [@pone.0087604-Solini1]                            Caucasian       CS          DN            non-ESRD                                    Albuminuria
  De Cosmo, 1999 [@pone.0087604-DeCosmo1]                         Caucasian       CC          DN            non-ESRD                                  UAE \>30 mg/day
  Miura, 1999 [@pone.0087604-Miura1]                                Asian         CS          DN            non-ESRD                                  UAE \>10 µg/min
  Kuramoto, 1999 [@pone.0087604-Kuramoto1]                          Asian         CS          DN            non-ESRD                                  UAE \>15 µg/min
  Huang, 1998 [@pone.0087604-Huang2]                              Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Walder, 1998 [@pone.0087604-Walder1]                            Caucasian       CC          DN            non-ESRD                                  UAE \>30 mg/day
  Freire, 1998 [@pone.0087604-Freire1]                            Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Grzeszczak, 1998 [@pone.0087604-Grzeszczak1]                    Caucasian       CS          DN            non-ESRD                  ACR \>1.9 mg/mol (men) or \>2.8 mg/mol (women)
  Young, 1998 [@pone.0087604-Young1]                                Asian         CS          DN            non-ESRD                                  UAE \>30 mg/day
  Penno, 1998 [@pone.0087604-Penno1]                              Caucasian       CS          DN            non-ESRD                                  UAE \>20 µg/min
  Fernández-Llama, 1998 [@pone.0087604-FernandezLlama1]           Caucasian       CS          HN            non-ESRD                                  UAE \>20 µg/min
  Frost, 1998 [@pone.0087604-Frost1]                              Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Pei, 1997 [@pone.0087604-Pei1]                                  Caucasian       CS          GN            non-ESRD                                 biopsy diagnosed
  Marre, 1997 [@pone.0087604-Marre1]                              Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Barnas, 1997 [@pone.0087604-Barnas1]                            Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Ringel, 1997 [@pone.0087604-Ringel1]                            Caucasian       CC          DN            non-ESRD                                  UAE \>30 mg/day
  Schmidt, 1997 [@pone.0087604-Schmidt1]                          Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Kawada, 1997 [@pone.0087604-Kawada1]                              Asian         CC         Comb             ESRD                                          RRT
  Kario, 1997 [@pone.0087604-Kario1]                                Asian         CS          HN            non-ESRD                                  UAE \>15 µg/min
  Nakajima, 1996 [@pone.0087604-Nakajima1]                          Asian         CS          DN            non-ESRD                                   ACR \>30 mg/g
  Chowdhury, 1996 [@pone.0087604-Chowdhury1]                      Caucasian       CS          DN            non-ESRD                                    Albuminuria
  McLaughlin, 1996 [@pone.0087604-McLaughlin1]                    Caucasian       CC         Comb           non-ESRD                              RRT or doctor diagnosed
  Oh, 1996 [@pone.0087604-Oh1]                                      Asian         CS          DN            non-ESRD                                  UAE \>20 µg/min
  Schmidt, 1996 [@pone.0087604-Schmidt2]                          Caucasian       CC         Comb             ESRD                                          RRT
  Doi, 1996 [@pone.0087604-Doi1]                                    Asian         CS          DN            non-ESRD                                   ACR \>30 mg/g
  Ohno, 1996 [@pone.0087604-Ohno1]                                  Asian         CS          DN            non-ESRD                                   ACR \>10 mg/g
  Mizuiri, 1995 [@pone.0087604-Mizuiri2]                            Asian         CC          DN            non-ESRD                              UAE \>20 µg/min or RRT
  Yorioka, 1995 [@pone.0087604-Yorioka1]                            Asian         CC          GN            non-ESRD                                 biopsy diagnosed
  Fujisawa, 1995 [@pone.0087604-Fujisawa1]                          Asian         CS          DN            non-ESRD                                Albuminuria or RRT
  Panagiotopoulos, 1995 [@pone.0087604-Panagiotopoulos1]          Caucasian       CS          DN            non-ESRD                                  UAE \>20 µg/min
  Tarnow, 1995 [@pone.0087604-Tarnow1]                            Caucasian       CC          DN            non-ESRD                       UAE \>300 mg/day or biopsy diagnosed
  Schmidt, 1995 [@pone.0087604-Schmidt3]                          Caucasian       CC          GN            non-ESRD                                 biopsy diagnosed
  Yoshida, 1995 [@pone.0087604-Yoshida1]                            Asian         CC          GN            non-ESRD                                 biopsy diagnosed
  Dudley, 1995 [@pone.0087604-Dudley1]                            Caucasian       CC          DN            non-ESRD               patients with urine in top tertile of the median UAE
  Harden, 1995 [@pone.0087604-Harden1]                            Caucasian       CC          GN            non-ESRD                                 biopsy diagnosed
  Doria, 1994 [@pone.0087604-Doria1]                              Caucasian       CC          DN            non-ESRD                                  UAE \>30 µg/min
  Marre, 1994 [@pone.0087604-Marre2]                              Caucasian       CS          DN            non-ESRD                                  UAE \>30 mg/day
  Powrie, 1994 [@pone.0087604-Powrie1]                            Caucasian       CS          DN            non-ESRD                                  ACR \>3 mg/mmol

CC: case control study; CS: cross-sectional survey; DN: diabetic nephropathy; non-DN: non diabetic nephropathy; GN: glomerulonephritis; HN: hypertensive nephropathy; Comb: combined; ESRD: only ESRD patients; non-ESRD: not only ESRD patients; UAE: urinary albumin excretion rate; ACR: Albumin creatinine ratio; eGFR: estimated glomerular filtration rate; CCr: creatinine clearance; RRT: renal replacement therapy; CT: computed tomography; SCr: serum creatinine.

10.1371/journal.pone.0087604.t002

###### Quality score and description of studies' population in included studies.

![](pone.0087604.t002){#pone-0087604-t002-2}

  First author & year                                             Quality score   Age (years)   Male (%)   BMI (kg/m^2^)   DM (%)   HT (%)   Case group   Control group                     
  -------------------------------------------------------------- --------------- ------------- ---------- --------------- -------- -------- ------------ --------------- ------ ----- ----- -----
  Shaikh, 2012 [@pone.0087604-Shaikh1]                                  7             58           54           27          100       86         18            98          52    123   148   25
  Rahimi, 2012 [@pone.0087604-Rahimi1]                                  7             56           40           27          100       63         19            66          55    14    32    26
  El-Baz, 2012 [@pone.0087604-ElBaz1]                                   6             59           53                       100                  4             58          40     5    72    23
  Zsom(1), 2011 [@pone.0087604-Zsom1]                                   4             64           55                                            39            88          68    44    110   46
  Zsom(2), 2011 [@pone.0087604-Zsom1]                                   4             70           61                       100                  20            60          34    44    110   46
  Al-Harbi, 2011 [@pone.0087604-AlHarbi1]                               4             58           48           30          100       86         12            39          59    25    75    96
  Jung, 2011 [@pone.0087604-Jung1]                                      7             34           57                                 61         78            142         41    98    164   38
  Ali, 2011 [@pone.0087604-Ali1]                                        5             55           55           25           16       41         47            125         18    86    90    14
  Huang, 2010 [@pone.0087604-Huang1]                                    3             40           50                                 54         10            29          8     58    52    10
  Jayapalan, 2010 [@pone.0087604-Jayapalan1]                            7             60           38                       100       42         77            77          21    31    31    19
  Mansoor, 2010 [@pone.0087604-Mansoor1]                                6             53           31           27          100       29         27            45          12    65    102   33
  Naresh, 2009 [@pone.0087604-Naresh1]                                  5             54           53           29          100       95         4             11          15    12    11     7
  Ezzidi, 2009 [@pone.0087604-Ezzidi1]                                  7             60           46           28          100       50         88            260        167    152   196   54
  Nikzamir, 2009 [@pone.0087604-Nikzamir1]                              7             59           56           26          100       54         31            84          64    42    75    28
  Anbazhagan, 2009 [@pone.0087604-Anbazhagan1]                          7             49           73                        28       75         33            58          27    23    53    22
  Ahluwalia, 2009 [@pone.0087604-Ahluwalia1]                            7             58           66           24          100       59         44            64         132    49    117   89
  Palomo-Piñón, 2009 [@pone.0087604-PalomoPinon1]                       7             60           48           27          100       26         87            105         43    85    91    24
  Möllsten, 2008 [@pone.0087604-Mollsten1]                              7             47           49                       100       52         25            69          27    36    113   48
  Eroglu, 2008 [@pone.0087604-Eroglu1]                                  7             58           41           29          100       38         13            17          16    13    24    19
  Arfa, 2008 [@pone.0087604-Arfa1]                                      7             62           43           29          100       68         9             41          40     6    24    21
  Tripathi, 2008 [@pone.0087604-Tripathi1]                              6             36           88                        0        69         53            72          55    379   148   42
  Movva, 2007 [@pone.0087604-Movva1]                                    6             57           70                       100                  47            88          39    74    74    27
  Uddin, 2007 [@pone.0087604-Uddin1]                                    4             51           54                       100       78         12            22          24    24    28    14
  Buraczynska, 2006 [@pone.0087604-Buraczynska1]                        8             51           56                        19       78        174            346        228    112   268   140
  So, 2006 [@pone.0087604-So1]                                          6                                                   100                 407            364         93    549   526   150
  Shestakova, 2006 [@pone.0087604-Shestakova1]                          6             26           48           23          100       26         15            35          13    24    30    12
  Ng, 2006 [@pone.0087604-Ng1]                                          7             61           61           32          100       48         47            148         96    32    83    52
  Prasad, 2006 [@pone.0087604-Prasad1]                                  7             57           33                       100       63         67            74          55    76    97    52
  Degirmenci, 2005 [@pone.0087604-Degirmenci1]                          4                                                   100                  6             25          12    19    47    30
  van der Sman-de Beer, 2005 [@pone.0087604-vanderSmandeBeer1]          6             59           61           26           17       65        110            227        116    112   235   125
  Park, 2005 [@pone.0087604-Park1]                                      5             60           58           23          100       83         27            49          27    30    51     7
  Canani, 2005 [@pone.0087604-Canani1]                                  6                                                   100                  66            181        126    120   308   181
  Fabris, 2005 [@pone.0087604-Fabris1]                                  7             60           78           26           0       100         13            32          41    34    83    55
  Lau, 2004 [@pone.0087604-Lau1]                                        5             43           48                                            53            48          17    47    43     4
  Suzuki, 2004 [@pone.0087604-Suzuki1]                                  5             36           56                                            42            54          21    111   106   53
  Stratta, 2004 [@pone.0087604-Stratta1]                                5             50           67                                 39         23            50          44    29    76    66
  Lochynska, 2003 [@pone.0087604-Lochynska1]                            5             42           74                        0        0          13            32          5     20    45    35
  Papp, 2003 [@pone.0087604-Papp1]                                      4             49           46                                 65         11            25          14    34    83    33
  Aucella, 2003 [@pone.0087604-Aucella1]                                5             62           54                        16       58         57            201        203    170   576   561
  Okuno, 2003 [@pone.0087604-Okuno1]                                    7             78           50           20          100       31         1              8          3     21    12     5
  Ortiz, 2003 [@pone.0087604-Ortiz1]                                    6             56           59           22           0       100         9             71          81    17    66    46
  Hadjadj, 2003 [@pone.0087604-Hadjadj1]                                9             66           73           29          100       72        552           1468        1119   115   282   208
  Wang, 2003 [@pone.0087604-Wang2]                                      5             55           51           23           30       66        106            104         36    71    88    24
  Dixit, 2002 [@pone.0087604-Dixit1]                                    7             24           55                                            12            26          9      3    24    13
  Lee(1), 2002 [@pone.0087604-Lee1]                                     8                                                    0                   20            45          12    330   277   66
  Lee(2), 2002 [@pone.0087604-Lee1]                                     8                                                   100                 117            137         40    208   170   39
  Losito, 2002 [@pone.0087604-Losito1]                                  6             67           61           25           14       50         27            81          52    22    84    63
  Yoon, 2002 [@pone.0087604-Yoon1]                                      5             35           56                        0        35         44            116         31    70    128   25
  Fradin, 2002 [@pone.0087604-Fradin1]                                  7             57           53           32          100       33         18            61          38    20    54    44
  Drouet, 2002 [@pone.0087604-Drouet1]                                  6             44           77                                            16            46          63    13    28    36
  Nicod, 2002 [@pone.0087604-Nicod1]                                    5             54           57           25                               63            156         41    54    153   53
  Araz, 2001 [@pone.0087604-Araz1]                                      7             56           41           28          100       63         18            64          34    23    57    43
  Azar, 2001 [@pone.0087604-Azar1]                                      6             23           46                       100                  2             27          23     2     7     1
  Lovati, 2001 [@pone.0087604-Lovati1]                                  7             54           57           25           12       51         63            156         41    69    195   63
  Wang, 2001 [@pone.0087604-Wang3]                                      8                                                                        28            99          41    313   662   311
  Taniwaki, 2001 [@pone.0087604-Taniwaki1]                              7             61           59           23          100       54         32            40          14    31    26    12
  Viswanathan, 2001 [@pone.0087604-Viswanathan1]                        7             57           66           26          100       64         17            45          24    10     8     5
  Hadjadj, 2001 [@pone.0087604-Hadjadj2]                                7             40           59           23          100       53         8             34          17    46    116   89
  Wu, 2000 [@pone.0087604-Wu1]                                          3             60           55                       100                  22            31          18    19    20     2
  Hsieh, 2000 [@pone.0087604-Hsieh1]                                    5             61           49           23          100       60         80            59          40    86    50    21
  van Ittersum, 2000 [@pone.0087604-vanIttersum1]                       6             55           59                       100       80         23            33          13    53    86    49
  Tomino, 1999 [@pone.0087604-Tomino1]                                  7             61           63                       100                 312            337         96    163   189   55
  Solini, 1999 [@pone.0087604-Solini1]                                  8             60           58           30          100       61         33            66          58    27    83    62
  De Cosmo, 1999 [@pone.0087604-DeCosmo1]                               7             43           61                       100       42         23            76          73    18    53    65
  Miura, 1999 [@pone.0087604-Miura1]                                    7             36           34                       100       21         36            49          13    35    58    10
  Kuramoto, 1999 [@pone.0087604-Kuramoto1]                              7             58           61           23          100       56         8             16          9     13    13     3
  Huang, 1998 [@pone.0087604-Huang2]                                    6                                                   100                  4             12          8      7    29    23
  Walder, 1998 [@pone.0087604-Walder1]                                  7             42           71                       100       86         12            25          18    12    16    16
  Freire, 1998 [@pone.0087604-Freire1]                                  6             28           48                       100       17         12            32          33    10    45    34
  Grzeszczak, 1998 [@pone.0087604-Grzeszczak1]                          7             62                        29          100       68        103            230        129    63    118   73
  Young, 1998 [@pone.0087604-Young1]                                    7             56           34           25          100       73         23            30          3     26    20     8
  Penno, 1998 [@pone.0087604-Penno1]                                    5                                                   100                  15            38          23    62    258   114
  Fernández-Llama, 1998 [@pone.0087604-FernandezLlama1]                 5                                                    0       100         1              6          7      5    38    18
  Frost, 1998 [@pone.0087604-Frost1]                                    5                                                   100                  10             7          16    21    48    46
  Pei, 1997 [@pone.0087604-Pei1]                                        6             49           68                                            32            81          55    21    49    30
  Marre, 1997 [@pone.0087604-Marre1]                                    8             43           57           24          100       57         50            168        119    40    69    48
  Barnas, 1997 [@pone.0087604-Barnas1]                                  6             47           70                       100       48         9             27          14    15    21     4
  Ringel, 1997 [@pone.0087604-Ringel1]                                  8             51           54           26          100       43         64            152         79    78    199   92
  Schmidt, 1997 [@pone.0087604-Schmidt1]                                7             65           51           29          100       74         61            129        121    62    154   131
  Kawada, 1997 [@pone.0087604-Kawada1]                                  5             59           62                        22                  89            89          30    84    96    28
  Kario, 1997 [@pone.0087604-Kario1]                                    6             72           41           25           0       100         42            62          29    86    98    16
  Nakajima, 1996 [@pone.0087604-Nakajima1]                              6             56           64                       100                  37            50          14    18    19     4
  Chowdhury, 1996 [@pone.0087604-Chowdhury1]                            6             39           55                       100       97         40            124         78    32    79    55
  McLaughlin, 1996 [@pone.0087604-McLaughlin1]                          4             42           57                                           114            366        312    75    203   93
  Oh, 1996 [@pone.0087604-Oh1]                                          6             35           42           19          100                  12             9          10    11    10     7
  Schmidt, 1996 [@pone.0087604-Schmidt2]                                5             55           58                                 63         27            51          28    21    38    36
  Doi, 1996 [@pone.0087604-Doi1]                                        7             62           51           22          100       55         50            85          29    56    56    12
  Ohno, 1996 [@pone.0087604-Ohno1]                                      7             61           53           23          100       56         26            38          15    33    15     9
  Mizuiri, 1995 [@pone.0087604-Mizuiri2]                                6             54                                    100       90         11            51          19    11    11     9
  Yorioka, 1995 [@pone.0087604-Yorioka1]                                5             33           44                                 6          27            13          8     46    47    10
  Fujisawa, 1995 [@pone.0087604-Fujisawa1]                              4                                                   100                  24            23          7     17    12     6
  Panagiotopoulos, 1995 [@pone.0087604-Panagiotopoulos1]                5             62           66                       100                  10            25          15    29    44    42
  Tarnow, 1995 [@pone.0087604-Tarnow1]                                  8             41           61           24          100       68         40            95          63    46    77    67
  Schmidt, 1995 [@pone.0087604-Schmidt3]                                6             45           75                                 59         44            81          79    40    117   77
  Yoshida, 1995 [@pone.0087604-Yoshida1]                                7             39           64                                 15         20            17          16    19    24     3
  Dudley, 1995 [@pone.0087604-Dudley1]                                  7             53           67           29          100       58         29            82          47    35    87    36
  Harden, 1995 [@pone.0087604-Harden1]                                  5             35                                                         19            41          40    17    42    39
  Doria, 1994 [@pone.0087604-Doria1]                                    5             29                                    100                  15            35          24    20    41    16
  Marre, 1994 [@pone.0087604-Marre2]                                    6             39           60           23          100                  4             35          23    15    28    19
  Powrie, 1994 [@pone.0087604-Powrie1]                                  6             35           50           20          100                  4              8          7     24    37    24

Quality score: result of quality assessed in each study (detailed data were shown in supplementary file); Age: mean age; Male: probability of male; BMI: mean body mass index; DM: prevalence of diabetes mellitus; HT: prevalence of hypertension; II: number of II genotype carries; ID: number of ID genotype carries; DD: number of DD genotype carries.

Preliminary Pooled Analyses {#s3b}
---------------------------

Our meta-analysis showed that a significantly increased CKD risk was associated with the D allele compared with the I allele in each subgroup. [Figure 2](#pone-0087604-g002){ref-type="fig"} shows that D allele carriers had an OR of 1.21 for risk of all-cause CKD compared with I allele carriers, and that these ORs were dissimilar in different ethnicities (*p* = 0.002). OR for CKD in Asian individuals carrying the D allele compared with those carrying the I allele was 1.40 (95% CI: 1.23--1.59), and in Caucasian individuals was 1.12 (95% CI: 1.04--1.21). A summary of the other results is shown in [Table 3](#pone-0087604-t003){ref-type="table"} and are very similar to those in [Figure 2](#pone-0087604-g002){ref-type="fig"}. In the allele type, genotype, and dominant/recessive models, individuals carrying the D allele showed higher CKD risk, and ORs were higher in Asians than in Caucasians. The heterogeneities were higher in Asian populations than in Caucasian populations in each subgroup.

![Forest plot of the association between ACE I/D and all-cause CKD using allele type model.](pone.0087604.g002){#pone-0087604-g002}

10.1371/journal.pone.0087604.t003

###### Odds ratio of ACE I/D and all-cause CKD, diabetic nephropathy, non-diabetic nephropathy using assumption of allele type, genotype, dominant and recessive model.

![](pone.0087604.t003){#pone-0087604-t003-3}

  Model                       Ethnicity    All-cause CKD   Diabetic nephropathy   Non-diabetic nephropathy                                                                        
  ------------------------- ------------- --------------- ---------------------- -------------------------- ------- ---- ------ -------------- ------- ---- ------ -------------- -------
  Allele type (D vs. I)      All studies        99                 1.21                 (1.13, 1.29)         0.076   65   1.23   (1.14, 1.33)   0.063   22   1.29   (1.06, 1.56)   0.166
                                Asian           38                 1.40                 (1.23, 1.59)         0.118   24   1.36   (1.18, 1.56)   0.070   10   1.59   (1.17, 2.17)   0.212
                              Caucasian         61                 1.12                 (1.04, 1.21)         0.053   41   1.17   (1.06, 1.29)   0.064   12   1.08   (0.91, 1.29)   0.054
  Genotype-1 (DD vs. II)     All studies        99                 1.44                 (1.26, 1.64)         0.277   65   1.48   (1.26, 1.74)   0.249   22   1.67   (1.16, 2.41)   0.556
                                Asian           38                 1.87                 (1.46, 2.38)         0.377   24   1.66   (1.27, 2.18)   0.230   10   2.77   (1.62, 4.75)   0.567
                              Caucasian         61                 1.25                 (1.07, 1.46)         0.224   41   1.39   (1.14, 1.71)   0.275   12   1.11   (0.77, 1.60)   0.211
  Genotype-2 (ID vs. II)     All studies        99                 1.20                 (1.10, 1.32)         0.098   65   1.26   (1.13, 1.40)   0.082   22   1.17   (0.92, 1.49)   0.206
                                Asian           38                 1.34                 (1.14, 1.57)         0.152   24   1.31   (1.09, 1.57)   0.088   10   1.43   (0.99, 2.05)   0.259
                              Caucasian         61                 1.13                 (1.02, 1.25)         0.062   41   1.23   (1.07, 1.42)   0.084   12   0.91   (0.74, 1.13)   0.570
  Dominant(DD+ID vs. II)     All studies        99                 1.28                 (1.16, 1.41)         0.132   65   1.33   (1.19, 1.50)   0.110   22   1.30   (1.00, 1.69)   0.271
                                Asian           38                 1.48                 (1.25, 1.74)         0.180   24   1.42   (1.19, 1.70)   0.095   10   1.66   (1.12, 2.45)   0.317
                              Caucasian         61                 1.17                 (1.05, 1.31)         0.100   41   1.28   (1.10, 1.49)   0.130   12   1.01   (0.80, 1.27)   0.031
  Recessive(DD vs. ID+II)    All studies        99                 1.27                 (1.15, 1.39)         0.090   65   1.26   (1.13, 1.42)   0.112   22   1.53   (1.18, 1.99)   0.262
                                Asian           38                 1.56                 (1.28, 1.90)         0.227   24   1.42   (1.12, 1.79)   0.169   10   2.22   (1.42, 3.48)   0.369
                              Caucasian         61                 1.16                 (1.04, 1.28)         0.090   41   1.21   (1.06, 1.37)   0.097   12   1.20   (0.92, 1.57)   0.118

Identifying Moderators of the Association between ACE I/D Polymorphisms and CKD Risk {#s3c}
------------------------------------------------------------------------------------

[Table 4](#pone-0087604-t004){ref-type="table"} shows the assessment results of moderate effect on all-cause CKD using the allele type model. Compared with I allele carriers, D allele carriers had a higher OR for CKD risk in Asians than in Caucasians (OR of moderate effect: 1.24; 95% CI: 1.08--1.42). Hypertension also was a moderator (OR of moderate effect: 1.55; 95% CI: 1.04--2.32) and still had a significant moderate effect after adjusting ethnicity (OR of moderate effect: 1.57; 95% CI: 1.07--2.31). No additional moderators were significant after adjustment for ethnicity and hypertension (data not shown). In the final model of these analyses, τ^2^ declined by 15.5% (crude: 0.097; after adjustment: 0.082) and *p* of Egger's regression test was not significant (*p* = 0.258). We did not find a significant gender-dependent effect.

10.1371/journal.pone.0087604.t004

###### Moderator effects of allele type model (D vs. I) on all-cause CKD.
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                                                                  Unadjusted                 Adjusted ethnicity                                          
  -------------------------------------------- ---- --------------------------------------- -------------------- --------------------------------------- --------------
  Ethnicity (Caucasian is ref.)                 99   1.24[\*](#nt106){ref-type="table-fn"}      (1.08, 1.42)                                             
  Study design (CS is ref.)                     99                   1.05                       (0.92, 1.20)                      1.03                    (0.90, 1.18)
  Quality score (per 1 score)                   99                   0.98                       (0.93, 1.04)                      0.99                    (0.94, 1.05)
  Kidney function of case (non-ESRD is ref.)    99                   1.03                       (0.87, 1.23)                      0.97                    (0.81, 1.16)
  Age (per 10 years)                            88                   1.02                       (0.95, 1.09)                      1.01                    (0.95, 1.08)
  Male (per 100%)                               84                   1.48                       (0.72, 3.01)                      1.63                    (0.81, 3.28)
  BMI (per 5 kg/m^2^)                           45                   0.86                       (0.73, 1.03)                      0.95                    (0.78, 1.16)
  DM (per 100%)                                 81                   0.96                       (0.78, 1.18)                      0.99                    (0.81, 1.22)
  Hypertension (per 100%)                       68   1.55[\*](#nt106){ref-type="table-fn"}      (1.04, 2.32)      1.57[\*](#nt106){ref-type="table-fn"}   (1.07, 2.31)

Depend variable: log odds ratio of ACE I/D and all-cause CKD using allele type model.

n: number of studies; OR: odds ratio for moderate effect; 95% CI: 95% confidence interval.

CS: cross-sectional study; non-ESRD: not only ESRD patients; Age: mean age; Male: probability of male; BMI: mean body mass index; DM: prevalence of diabetes mellitus; Hypertension: prevalence of hypertension.

: p\<0.05.

In subgroup analyses of diabetic nephropathy, study design (OR for moderate effect: 1.21; 95% CI: 1.02--1.42) and body mass index (OR of moderate effect: 0.84; 95% CI: 0.70--1.00) had significant moderate effects on ACE I/D polymorphisms and diabetic nephropathy. After adjustment for ethnicity, the moderate effects of study design (OR of moderate effect: 1.19; 95% CI: 1.01--1.41) was still significant but that of body mass index (OR for moderate effect: 0.91; 95% CI: 0.73--1.13) was not (data not shown). The results of the nondiabetic nephropathy subgroup were similar to those for all-cause CKD, with ethnicity (OR of moderate effect: 1.69; 95% CI: 1.07--2.68) and hypertension (OR of moderate effect: 2.42; 95% CI: 1.19--4.93) the only two significant moderators in multivariable analyses (data not shown).

Estimated Gender-dependent Effects {#s3d}
----------------------------------

[Table 5](#pone-0087604-t005){ref-type="table"} shows the interaction of ethnicity and gender. We found no significant interactions between the other variables and gender. Coefficients of interaction were significant for hypertension (*p* before adjustment for hypertension = 0.015; *p* after adjustment for hypertension = 0.003). No other moderators were significant when added to the final model. A proportion of 32.8% of heterogeneity (crude τ^2^ = 0.100; after adjustment, τ^2^ = 0.068) was caused by different ethnicity, gender probability, and prevalence of hypertension in the study population, and *p* of Egger's regression test was not significant (*p* = 0.217). [Figure 3](#pone-0087604-g003){ref-type="fig"} shows OR of ACE I/D polymorphisms and CKD risk in different combination of ethnicity, gender, and hypertension status based on Model 2 in [Table 5](#pone-0087604-t005){ref-type="table"}. A gender-dependent effect analysis showed the strongest association between the ACE I/D polymorphisms and CKD risk in Asian males with hypertension (OR: 3.75; 95% CI: 1.84--7.65) or without (OR: 2.42; 95% CI: 1.40--4.20).

![Gender-dependent effects of ACE I/D and all-cause CKD in each population.\
Left figure was showed the OR in people without hypertension; right figure was showed the odds ratio in patient with hypertension. Red triangle and square: individual studies in Caucasian; blue triangle and square: individual studies in Asian. Solid line: unbiased estimator of odds ratio; dashed line: 95% confidence interval of odds ratios. Estimated value of log odds ratio in individual studies without hypertension used following formula: observed log odds ratio -- hypertension prevalence of study population×0.437 (according to Model 2 in [Table 5](#pone-0087604-t005){ref-type="table"}) Estimated value of log odds ratio in individual studies with hypertension used following formula: observed log odds ratio+(1-- hypertension prevalence of study population)×0.437 (according to Model 2 in [Table 5](#pone-0087604-t005){ref-type="table"}).](pone.0087604.g003){#pone-0087604-g003}

10.1371/journal.pone.0087604.t005

###### Three way interaction of Asian, male and ACE D allele on all-cause CKD, diabetic nephropathy and non-diabetic nephropathy.
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                                               All-cause CKD                Diabetic nephropathy          Non-diabetic nephropathy                                                                                                             
  ------------------------------- ---------------------------------------- ---------------------- ----------------------------------------- ---------------------------------------- -------- ------- ---------------------------------------- -------
  **Intercept**                                    0.297                           0.275                            0.115                                    0.291                    0.090    0.369                   −0.213                   0.746
  **Race (Caucasian is ref.)**                     −0.697                          0.391           −0.853[\*](#nt113){ref-type="table-fn"}                   0.402                    −0.817   0.569                   −1.080                   0.816
  **Male (per 100%) €**                            −0.312                          0.476                           −0.470                                    0.501                    −0.122   0.691                   −0.349                   1.050
  **Race×Male**                    1.662[\*](#nt113){ref-type="table-fn"}          0.686           2.094[\*](#nt113){ref-type="table-fn"}                    0.715                    2.064    1.082   2.666[\*](#nt113){ref-type="table-fn"}   1.231
  **Hypertension (per 100%) €**                                                                    0.437[\*](#nt113){ref-type="table-fn"}                    0.192                    0.229    0.294   0.857[\*](#nt113){ref-type="table-fn"}   0.245
  **τ^2^**                                         0.075                           0.068                            0.081                    0.036[\*](#nt113){ref-type="table-fn"}                                                            
  **Egger's test**                               p = 0.097                       p = 0.217                        p = 0.385                                p = 0.032                                                                           

Depend variable: log odds ratio of ACE I/D and CKD using allele type model.

β: coefficients in meta-regression; se: standard error of β.

Model 1: Hypertension was not included in independent variables.

Model 2: Hypertension was included in independent variables.

Egger's test: p-value of Egger's regression test.

€: references of parameters were 0%.

: p\<0.05.

Interaction of ethnicity and gender was borderline significant (*p* = 0.056) in the diabetic nephropathy subgroup, but was significant (*p* = 0.030) in the nondiabetic nephropathy subgroup. Although the result of symmetry assessment was significant in nondiabetic nephropathy subgroup (*p* of Egger's regression test = 0.032), it was noteworthy that 78.3% of heterogeneity (crude τ^2^∶0.166; after adjustment, τ^2^∶0.036) were caused by ethnicity, gender, and hypertension.

The symmetry of final models was shown in [Figure 4](#pone-0087604-g004){ref-type="fig"}. Funnel plots presented the association between residual and standard error based on results of [Table 5](#pone-0087604-t005){ref-type="table"}, and each point represents a study. Egger's regression test indicated no evidence of publication bias among studies included into the final model this meta-analysis and diabetic nephropathy subgroup. The model in nondiabetic nephropathy subgroup was asymmetric, and it might be due to the study reported by Jung et al. [@pone.0087604-Jung1]. We did sensitivity analyses leaving the article out (data not shown). The result of symmetry assessment was not significant (*p* of Egger's regression test = 0.245), and the coefficients in this model were still significant (*p* of interaction effect of ethnicity and gender = 0.002; *p* of moderate effect of hypertension \<0.001). In addition, the τ^2^ was 0 in this sensitivity model.

![Funnel plot of three way interaction model in each subgroup.\
The model in nondiabetic nephropathy subgroup was asymmetric. The triangle in that plot was study reported by Jung et[@pone.0087604-Jung1], and the p value of the student residual was less 0.05. After excluding this study, the p value of Egger's regression test was not significant (*p* = 0.245) and the moderate effect of interaction and hypertension were more significantly (*p* of interaction: 0.0304→0.0023; *p* of hypertension: 0.0005→\<0.0001).](pone.0087604.g004){#pone-0087604-g004}

Discussion {#s4}
==========

This study showed that CKD risk was higher in D allele carriers than in I allele carriers, and there was no strong evidence that analyses using different model assumptions might produce dissimilar results. Heterogeneity was higher in the Asian population than in the Caucasian population. Interaction between ACE I/D polymorphisms and hypertension exerted an additive effect on CKD risk. A gender-dependent effect of ACE I/D polymorphisms on CKD risk was clearly apparent in Asians but not in Caucasians.

The DD genotype showed higher gene expression and serum ACE levels than the ID genotype, followed by the II genotype [@pone.0087604-Mizuiri1], [@pone.0087604-Rigat1]. High blood ACE levels may increase blood angiotensin II levels [@pone.0087604-Remuzzi1], and individuals with higher angiotensin II levels may have a higher CKD risk [@pone.0087604-Wolf1], [@pone.0087604-RuizOrtega1]. Previous studies showed that the association between ACE I/D polymorphisms and CKD risk might not be dominant or recessive [@pone.0087604-Remuzzi1], [@pone.0087604-Mizuiri1], [@pone.0087604-Rigat1]. Previous meta-analysis studies showed the supported results, they reported that DD genotype had higher risk of CKD than ID genotype, followed by the II genotype. We also observed the apparent linear association between numbers of D allele and odds ratios compared the II genotype in genotype analyses [@pone.0087604-Qin1]--[@pone.0087604-Zhou1], [@pone.0087604-Zhou2]--[@pone.0087604-Yu1]. The assumption of the allele type model in this association might be more reasonable, and it may thus be true that individuals carrying the D allele have a higher CKD risk.

Hypertension in some patients is due to a dysfunction of RAS such as abnormal secretion of renin, causing increased blood angiotensin I levels [@pone.0087604-Kobori1]. D allele carriers had higher ACE levels than I allele carriers [@pone.0087604-Rigat1], leading to more efficient conversion of angiotensin I to angiotensin II, resulting in CKD [@pone.0087604-Wolf1], [@pone.0087604-RuizOrtega1]. The mechanism may be an additive effect of hypertension and the D allele. An additive effect was significant in the nondiabetic group but not in the diabetic nephropathy subgroups. The blood levels of advanced glycation end products (AGE) diabetic patients may be high, possibly causing blood pressure increases [@pone.0087604-Ahmed1]. We accordingly hypothesize that the probability of hypertension because of a dysfunction of RAS was higher in the nondiabetic nephropathy subgroup than in the diabetic nephropathy subgroup. Thus, the interaction between ACE I/D polymorphisms and hypertension was significant only in the nondiabetic nephropathy subgroup. This hypothesis may require further studies for confirmation.

We found a significant gender-dependent effect of ACE I/D polymorphisms on CKD risk in Asians. In previous studies in Asians, the ORs of the additive effect on the DD genotype of males were 2.94 and 1.41 in Japanese [@pone.0087604-Nakajima1] and Koreans [@pone.0087604-Park1], respectively. Another study in Japan also reported a positive additive effect of the DD genotype of males [@pone.0087604-Tomino1]. Studies of Caucasians reported contrary results, with an interaction OR of 0.42 in Pakistan [@pone.0087604-Mansoor1]. Another two studies in France [@pone.0087604-Hadjadj1] and Mexico [@pone.0087604-PalomoPinon1] also showed an additive effect between the DD genotype and female gender but not male gender. Although the interaction tests in these studies were not significant, we could observe dissimilar gender-dependent effect in different ethnicity. Previous studies have also reported a different gender-dependent effect of ACE I/D polymorphisms on blood ACE levels in Asians and Caucasians. In a study conducted in China [@pone.0087604-Zhang2], differences in blood ACE levels between DD genotype and other genotypes among men were significantly greater than those in women. On the other hand, a study conducted in Germany [@pone.0087604-Biller1] reported the opposite result.

Androgens may play a key role in this additive effect. A study has shown that in intact male rats and ovariectomized female rats that received testosterone for 5 weeks, the androgen may have contributed to the decrease in pressure natriuresis [@pone.0087604-Reckelhoff1]. In an animal study, ACE activity was higher in male mice than in female mice, and this gender difference disappeared after gonadectomy [@pone.0087604-Lim1]. In previous reports, sensitivity to androgens was stated to be higher in Caucasians than in Asians [@pone.0087604-Ewing1]. Blood androgen levels in Caucasians and Asians showed no significant differences [@pone.0087604-Setiawan1], [@pone.0087604-Ellis1]. On the basis of previous studies, we hypothesized that the dissimilar gender-dependent effect of ACE I/D polymorphisms on CKD risk in Caucasians and Asians might be accounted for by dissimilar sensitivity to androgens. The gender difference of male sex hormone utilization was higher in Asians than in Caucasians. Therefore, that the additive effect of the D allele and male gender was also higher in Asians than in Caucasians.

In subgroup analyses, the above additive effect was borderline significant in the diabetic nephropathy subgroup, but there was no evidence that diabetic mellitus might contribute to this additive effect. Although the additive effect also could explain why two populations with different ethnicities had different heterogeneity before adjustment for any moderators, the calculated risk ratio of ACE I/D polymorphisms on CKD risk may have been affected by the gender-dependent effect in Asians.

Our study had three limitations. First, we relied on tabular data rather than on individual patient data, possibly leading to an inflated standard error in pooled analyses. However, we still observed a significant gender-dependent effect difference in different ethnicities. Second, estimates of diabetes mellitus and hypertension prevalence did not factor in the effects of therapy for them. Some subjects having higher blood glucose and blood pressure may have taken drugs, leading to normal biochemical values in reports. Third, we may have missed unpublished data for the nondiabetic nephropathy subgroup. But the results of this subgroup were similar to the results of previous studies and we still observed a significant result excluding the greatest impact of symmetry study; therefore, there is no evidence to question their reliability.

In conclusion, CKD risk was higher with the D allele than with the I allele. Asian ethnicity and hypertension had positive moderate effects, and their effects were more likely to be higher in patients with nondiabetic nephropathy. A gender-dependent effect of ACE I/D polymorphisms on CKD risk was confirmed in Asians; the D allele showed 3.75-fold greater risk for CKD than the I allele in hypertensive Asian males. These results suggest that Asian males should be offered testing for defects in ACE I/D polymorphisms, especially if they are hypertensive. We suggest that physicians should provide specific protection to D-allele carriers, for example by administering ACE inhibitors to hypertensive patients.
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